CIK: 0001831942 · Show all filings
Period: Q4 2020 (Next →)
Filing Date: Feb 16, 2021
Total Value ($000): $183,931 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CCCC | C4 THERAPEUTICS INC | 481,094 | $15,939 | 8.7% | $29.00 | 0.0% | COM STK | 12529R107 |
| — | TRILLIUM THERAPEUTICS INC | 852,871 | $12,546 | 6.8% | $14.71 | — | COM NEW | 89620X506 |
| — | CONSTELLATION PHARMCETICLS I | 423,708 | $12,203 | 6.6% | $28.80 | — | COM | 210373106 |
| — | FIVE PRIME THERAPEUTICS INC | 532,000 | $9,049 | 4.9% | $17.01 | — | COM | 33830X104 |
| — | KRONOS BIO INC | 298,839 | $8,926 | 4.9% | $29.87 | — | COM | 50107A104 |
| — | IVERIC BIO INC | 1,274,261 | $8,805 | 4.8% | $6.91 | — | COM | 46583P102 |
| ACRS | ACLARIS THERAPEUTICS INC | 1,336,275 | $8,646 | 4.7% | $4.22 | 0.0% | COM | 00461U105 |
| COGT | COGENT BIOSCIENCES INC | 760,025 | $8,535 | 4.6% | $10.99 | 0.0% | COM | 19240Q201 |
| — | CYMABAY THERAPEUTICS INC | 1,486,107 | $8,530 | 4.6% | $5.74 | — | COM | 23257D103 |
| PMVP | PMV PHARMACEUTICALS INC | 125,000 | $7,689 | 4.2% | $39.23 | 0.0% | COM | 69353Y103 |
| SNDX | SYNDAX PHARMACEUTICALS INC | 330,315 | $7,346 | 4.0% | $20.74 | 0.0% | COM | 87164F105 |
| XENE | XENON PHARMACEUTICALS INC | 467,368 | $7,188 | 3.9% | $11.70 | 0.0% | COM | 98420N105 |
| PTGX | PROTAGONIST THERAPEUTICS INC | 347,500 | $7,006 | 3.8% | $21.52 | 0.0% | COM | 74366E102 |
| MREO | MEREO BIOPHARMA GROUP PLC | 1,854,278 | $6,638 | 3.6% | $3.58 | — | ADS | 589492107 |
| CLDX | CELLDEX THERAPEUTICS INC NEW | 356,431 | $6,245 | 3.4% | $18.00 | 0.0% | COM NEW | 15117B202 |
| — | VISTAGEN THERAPEUTICS INC | 3,150,000 | $6,111 | 3.3% | $1.94 | — | COM NEW | 92840H202 |
| RLMD | RELMADA THERAPEUTICS INC | 178,565 | $5,727 | 3.1% | $34.36 | 0.0% | COM | 75955J402 |
| SPRY | SILVERBACK THERAPEUTICS INC | 97,143 | $4,502 | 2.4% | $33.40 | 0.0% | COM | 82835W108 |
| KURA | KURA ONCOLOGY INC | 133,503 | $4,360 | 2.4% | $35.14 | 0.0% | COM | 50127T109 |
| — | SURFACE ONCOLOGY INC | 467,796 | $4,322 | 2.3% | $9.24 | — | COM | 86877M209 |
| GNCAQ | GENOCEA BIOSCIENCES INC | 1,765,901 | $4,273 | 2.3% | $2.28 | 0.0% | COM NEW | 372427401 |
| — | MERSANA THERAPEUTICS INC | 158,827 | $4,226 | 2.3% | $26.61 | — | COM | 59045L106 |
| IMVT | IMMUNOVANT INC | 83,782 | $3,870 | 2.1% | $46.23 | 0.0% | COM | 45258J102 |
| IVA | INVENTIVA SA | 231,000 | $3,350 | 1.8% | $14.50 | — | ADS | 46124U107 |
| — | BCLS ACQUISITION CORP | 250,000 | $2,785 | 1.5% | $11.14 | — | COM CL A | G0904B105 |
| — | CYCLACEL PHARMACEUTICALS INC | 264,690 | $2,067 | 1.1% | $7.81 | — | COM | 23254L603 |
| — | MILLENDO THERAPEUTICS INC | 925,000 | $1,980 | 1.1% | $2.14 | — | COM | 60040X103 |
| — | LIFESCI ACQUISITION II CORP | 100,000 | $1,067 | 0.6% | $10.67 | — | COM | 53229E103 |